XBiotech Inc. (NASDAQ:XBIT - Get Free Report) shares passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.86 and traded as low as $2.58. XBiotech shares last traded at $2.66, with a volume of 74,953 shares traded.
XBiotech Stock Performance
The business has a fifty day moving average of $2.86 and a 200-day moving average of $3.48. The company has a market capitalization of $81.10 million, a P/E ratio of -2.06 and a beta of 0.97.
XBiotech (NASDAQ:XBIT - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On XBiotech
Several large investors have recently bought and sold shares of XBIT. Bank of New York Mellon Corp lifted its stake in XBiotech by 7.5% during the 4th quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company's stock valued at $360,000 after acquiring an additional 6,328 shares in the last quarter. Virtu Financial LLC bought a new position in XBiotech during the 4th quarter valued at $58,000. JPMorgan Chase & Co. lifted its stake in XBiotech by 68.2% during the 4th quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after acquiring an additional 5,930 shares in the last quarter. Barclays PLC lifted its stake in XBiotech by 13.9% during the 4th quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after acquiring an additional 3,661 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in XBiotech by 15.2% during the 4th quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock valued at $835,000 after acquiring an additional 27,909 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
